Mahapatra Baishakhi, Singh Abhishek, Banerjee Arpita, Sirohi Shruti, Singh Samer, Dubey Vikash K, Singh Rakesh K
Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
Centre of Experimental Medicine and Surgery, Institute of Medical Science, Banaras Hindu University, Varanasi 221005, India.
Vaccine. 2024 Dec 2;42(26):126373. doi: 10.1016/j.vaccine.2024.126373. Epub 2024 Sep 16.
Antigenic inefficacy to induce robust immune responses and durable memory are major causes of constantly failing prophylactic approaches in leishmaniasis. Here, we determine the potential of a standardized whole-killed Leishmania vaccine (Leishvacc) adjuvanted with anti-CD200 and anti-CD300a antibodies, either alone or with monophosphoryl lipid A (MPL-SE) emulsified in squalene oil, in restoring the compromised antigen presenting abilities of dendritic cells (DCs), effector properties of CD4T cells and providing protection against Leishmania donovani parasites. In animals vaccinated with antibodies adjuvanted vaccines, either alone or with MPL-SE, the antigen presenting abilities of CD11c DCs against Leishmania antigens, measured in terms of CD80, CD86, MHC-I, and MHC-II surface receptors and intracellular IL-12 were found enhanced than non-adjuvanted vaccine. We observed more proliferative and pro-inflammatory cytokines i.e. IL-2, IFN-γ, IL-23, and IL-12 producing CD4T cells in antibodies/MPL-SE adjuvanted vaccinated animals further suggesting that this approach helps antigen activated CD4T cells to acquire pro-inflammatory cytokines producing abilities. In antibodies, either alone or with MPL-SE, vaccinated animals, the number of CD4 central memory T cells and their longevity were found significantly enhanced that further evidenced the impact of this vaccination approach in inducing long term protective immunity. The animals, receiving antibodies adjuvanted vaccines, either alone or with MPL-SE, exhibited excellent protection against virulent parasites by restricting their growth, which correlated with the significantly reduced parasitemia, splenomegaly, and hepatomegaly, along with fewer numbers of liver granulomas. Our findings provide an insight to a new immunoprophylactic approach against visceral leishmaniasis, which not only satisfies the safety criteria, but also provides a robust immunogenic response with remarkable potential for parasites control. However, further in-depth investigations are needed to ascertain its ability in inducing long-lasting immunity.
抗原诱导强大免疫反应和持久记忆的无效性是利什曼病预防性治疗方法不断失败的主要原因。在此,我们确定了一种标准化的全灭活利什曼原虫疫苗(Leishvacc)的潜力,该疫苗单独或与抗CD200和抗CD300a抗体佐剂结合,或与角鲨烯油中乳化的单磷酰脂质A(MPL-SE)结合,以恢复树突状细胞(DC)受损的抗原呈递能力、CD4T细胞的效应特性,并提供针对杜氏利什曼原虫寄生虫的保护。在用抗体佐剂疫苗接种的动物中,单独或与MPL-SE结合,通过CD80、CD86、MHC-I和MHC-II表面受体以及细胞内IL-12测量的CD11c DC对利什曼原虫抗原的抗原呈递能力比未加佐剂的疫苗增强。我们在抗体/MPL-SE佐剂接种的动物中观察到更多产生增殖性和促炎细胞因子即IL-2、IFN-γ、IL-23和IL-12的CD4T细胞,进一步表明这种方法有助于抗原激活的CD4T细胞获得产生促炎细胞因子的能力。在单独或与MPL-SE结合的抗体接种的动物中,发现CD4中央记忆T细胞的数量及其寿命显著增加,这进一步证明了这种疫苗接种方法在诱导长期保护性免疫方面的影响。接受抗体佐剂疫苗的动物,单独或与MPL-SE结合,通过限制其生长对强毒寄生虫表现出优异的保护作用,这与显著降低的寄生虫血症、脾肿大和肝肿大以及较少的肝肉芽肿数量相关。我们的研究结果为内脏利什曼病的一种新的免疫预防方法提供了见解,该方法不仅满足安全标准,而且提供了强大的免疫原性反应,具有控制寄生虫的显著潜力。然而,需要进一步深入研究以确定其诱导持久免疫的能力。